...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Transactions of the Royal Society of Tropical Medicine and Hygiene >Antigen-specific activation and proliferation of CD4+ and CD8+ T lymphocytes from brucellosis patients.
【24h】

Antigen-specific activation and proliferation of CD4+ and CD8+ T lymphocytes from brucellosis patients.

机译：来自布鲁氏菌病患者的CD4 +和CD8 + T淋巴细胞的抗原特异性激活和增殖。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Salt-extractable antigen from Brucella melitensis 16M (RCM-BM) was used to evaluate the immune response from acute and chronic patients suffering from Brucella infections (in Mexico); their responses were compared with those of healthy controls. As a readout we used upregulation of CD69 (a well-established early activation marker for lymphocytes), lymphocyte proliferation by 3[H]thymidine or 5-bromo-2-deoxyuridine (BrdU) incorporation measured by liquid scintillation or flow cytometry, respectively, and production of gamma interferon (IFN gamma). We compared the antigen-specific response with the response induced by phytohaemagglutinin (PHA) as a positive control. There was no difference between acute patients and the healthy controls in the percentages of CD3+, CD4+ or CD8+ lymphocytes. However, we found that chronic patients had a significant (P < 0.05) increase in the CD8+ T cells, in line with previous studies. Antigen-specific responses to RCM-BM showed a significant (P < 0.05) upregulation of CD69 in both CD4+ and CD8+ T lymphocytes in acute brucellosis patients and in CD8+ T lymphocytes in chronic patients, indicating that both populations became activated by this antigen preparation. Moreover, lymphocyte proliferation from both acute and chronic patients in response to RCM-BM was highly significant (P < 0.001) when compared with healthy controls. However, there were no apparent differences between acute and chronic patients. Although the incorporation of BrdU showed similar results it provided additional information, since we demonstrated that both CD4+ and CD8+ T lymphocytes from acute and chronic patients proliferated equally well in response to RCM-BM. Similar results were observed with intracellular IFN gamma determination. As a whole, our data suggest an important role for both CD4+ and CD8+ T lymphocytes in Brucella infection in humans. As has been reported in mice, it is feasible that activated CD8+ T cells participate in protection against Brucella in humans through cytotoxicity or/and by the production of factors such as interferon and granulysin. The role of these cells should be carefully analysed to understand better their participation in human infection by Brucella.
机译：来自墨西哥布鲁氏菌16M的盐提取抗原（RCM-BM）用于评估患有布鲁氏菌感染的急慢性患者的免疫反应（在墨西哥）;将他们的反应与健康对照者的反应进行比较。作为读数，我们使用了CD69（一种公认的淋巴细胞早期活化标记）的上调，通过3 [H]胸苷或5-溴-2-脱氧尿苷（BrdU）掺入分别通过液体闪烁或流式细胞术测量的淋巴细胞增殖，和生产γ干扰素（IFNγ）。我们将抗原特异性应答与植物血凝素（PHA）诱导的应答作了阳性对照。急性患者和健康对照者的CD3 +，CD4 +或CD8 +淋巴细胞百分比没有差异。但是，我们发现，慢性患者的CD8 + T细胞显着增加（P <0.05），与以前的研究一致。对RCM-BM的抗原特异性反应显示，急性布鲁氏菌病患者的CD4 +和CD8 + T淋巴细胞以及慢性病患者的CD8 + T淋巴细胞均显着（P <0.05）CD69上调，表明这两种抗原均被该抗原制剂激活。此外，与健康对照组相比，急性和慢性患者对RCM-BM的淋巴细胞增殖都非常显着（P <0.001）。但是，急性和慢性患者之间没有明显差异。尽管BrdU的掺入显示出相似的结果，但它提供了更多的信息，因为我们证明了来自急性和慢性患者的CD4 +和CD8 + T淋巴细胞对RCM-BM的增殖均表现良好。用细胞内IFNγ测定观察到相似的结果。总体而言，我们的数据表明CD4 +和CD8 + T淋巴细胞在人布鲁氏菌感染中都起着重要作用。如在小鼠中所报道的，通过细胞毒性或/和通过产生诸如干扰素和颗粒溶素的因子，活化的CD8 + T细胞参与针对人类布鲁氏菌的保护是可行的。应该仔细分析这些细胞的作用，以更好地了解它们参与布鲁氏菌感染人类的​​过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号